Close
Solutions
Online Inquiry
Global Services

Lymphocyte Antigen Reactivity and Cytotoxicity Assay

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

With substantial experience in T cell receptor (TCR) engineering and TCR transfer gene therapy, Creative Biolabs provides a broad range of assay services to evaluate the antigen specific reactivity and cytotoxicity of TCR-modified T lymphocytes. Taking advantage of state-of-the-art instruments and experienced Ph.D level TCR specialists, we are capable of designing and performing custom analysis service to obtain comprehensive information about the reactivity and cytotoxicity of your specific TCRs.

Lymphocyte antigen reactivity and cytotoxicity assay

Recently, an innovative immunotherapy approach involving substituting redirected T cells using predefined certain antigen-specific TCR gene transfer has shown great promise in treating multiple caners and infection diseases. Gene modified TCR therapy is employing certain delivery vehicle to transfer the α-and β-chains genes of a specific TCR into autologous or donor-derived T cells, as a result, the specificity of those T cells can be redirected and large populations of antigen-specific T cells can be generated with high avidity for the antigen of interest. A successful engineered T cell with antigen–specific TCR can harness their own cytotoxicity to the target and eradicate tumors or other diseased cells, therefore, it is critical to analyze the lymphocyte antigen reactivity and cytotoxicity (target-killing activity) with appropriate approaches, which is also an approach to evaluate the effiency of your TCR. Creative Biolabs has various assay methods available for customers to measure the antigen specificity and cytotoxicity of TCR-modified T cells. According to the fact that the activation of T lymphocytes, both in vivo and in vitro, induces expression of CD69, we strongly recommended CD69 induction assay based on the flow cytometric analysis of CD69 expression to analyze the antigen-specificity of the cloned TCR α/β pairs. Additionally, the specificity and biologic activity of TCR gene-transduced T-cells can be determined by cytokine production, using enzyme-linked immunosorbent assay (ELISA) for the detection of cytokine secretion can be an alternative approach. The ability of the transduced cells to lyse target cancer cells (cytotoxicity) can be measured by the chromium release assay and the calcein-AM release assay. Other methods suitable for the analysis of antigen specificity and cytotoxicity are also available upon request. Meanwhile, Creative Biolabs is willing to custom a one-stop evaluation procedure according to your requirement.

Customers choosing our lymphocyte antigen reactivity and cytotoxicity assay service of TCR gene-transduced T-cells will benefit from our advanced instruments and extensive expertise. We are dedicated to offer top-quality service to meet every customer's requirements.

Reference:

High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens.2003. The Journal of Immunology.

To discuss your demands or to request a proposal, please contact us by .

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.